Repatha (Evolocumab) Safety in Adults 65 and Older

Why Geriatric Safety Data Matter for PCSK9 Inhibitors

Adults aged 65 and older carry the highest absolute burden of atherosclerotic cardiovascular disease (ASCVD), making them the population most likely to benefit from aggressive LDL-C lowering [1]. They are also the population most vulnerable to polypharmacy, cognitive decline, falls, and renal impairment. Any add-on injectable therapy must clear a higher safety bar in this age group.

The 2018 ACC/AHA cholesterol guideline explicitly recommends considering PCSK9 inhibitors for patients with clinical ASCVD who remain above LDL-C thresholds despite maximally tolerated statin therapy, without an upper age cutoff for candidacy [2]. The European Society of Cardiology (ESC) 2019 dyslipidemia guideline similarly endorses PCSK9 inhibitors for very-high-risk patients regardless of age, stating that "the benefit of LDL-C lowering applies across age groups studied in randomized trials" [3]. Because older adults were well represented in the major evolocumab trials, prescribers can draw on a substantial evidence base rather than extrapolating from younger cohorts.

FOURIER Trial: Age-Stratified Efficacy and Safety

The FOURIER trial randomized 27,564 patients with established ASCVD to evolocumab or placebo on background statin therapy [1]. Median follow-up was 2.2 years. The primary composite endpoint (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization) occurred 15% less often in the evolocumab arm (HR 0.85 to 95% CI 0.79 to 0.92, P<0.001).

A prespecified age subgroup analysis showed that the relative hazard reduction was consistent across patients younger than 65, those 65 to 74, and those 75 and older [1]. The absolute risk reduction was numerically larger in older age strata because baseline event rates were higher. Safety event rates, including injection site reactions, myalgia, and neurocognitive complaints, did not differ by age category.

The open-label extension study (FOURIER-OLE) followed 6,635 patients for a median of 5 additional years [4]. Among participants aged 65 and older, discontinuation rates were comparable to those in younger participants, and no new safety signals emerged with extended exposure. The annual rate of serious adverse events attributed to evolocumab remained below 1% across all age groups.

Neurocognitive Safety: The EBBINGHAUS Substudy

Cognitive decline ranks among the top concerns older patients and their families raise when considering any lipid-lowering intensification. The EBBINGHAUS trial (N=1,974) was designed specifically to test whether the very low LDL-C levels achieved with evolocumab (median 30 mg/dL) would impair cognitive function [5].

Results were clear. Over a median of 19 months, there was no significant difference between evolocumab and placebo on the Cambridge Neuropsychological Test Automated Battery (CANTAB), which assessed working memory, processing speed, and executive function. Dr. Robert Giugliano, the lead investigator, stated: "We found no adverse effect of evolocumab on cognitive function, even among patients who achieved very low LDL cholesterol levels below 25 mg/dL" [5].

This is consistent with a broader Mendelian randomization analysis published in JAMA Neurology showing that genetically determined low LDL-C (via PCSK9 loss-of-function variants) is not associated with increased dementia risk [6]. For geriatric patients already worried about memory, these data provide direct reassurance. Short sentences help here. The drug does not cause cognitive harm.

Renal Function and Dose Adjustments

Chronic kidney disease (CKD) prevalence exceeds 40% in adults over 65 [7]. Any drug added to a geriatric regimen must be evaluated for renal clearance and nephrotoxicity. Evolocumab, as a monoclonal antibody, is cleared by the reticuloendothelial system rather than by renal filtration. The FDA-approved prescribing information states that no dose adjustment is required for patients with mild, moderate, or severe renal impairment [8].

A post-hoc analysis of FOURIER stratified patients by baseline eGFR (<60, 60 to 89, and ≥90 mL/min/1.73 m²) [9]. Evolocumab reduced LDL-C by approximately 59% regardless of renal function category, and the incidence of adverse events, including proteinuria and acute kidney injury, was similar between treatment and placebo arms within each eGFR stratum. For the geriatric patient with stage 3 CKD on a statin and ezetimibe who still needs further LDL-C reduction, evolocumab requires no renal dose titration or additional monitoring beyond standard lipid panels.

Falls, Fractures, and Musculoskeletal Concerns

Statin-associated muscle symptoms (SAMS) affect 7 to 29% of statin users depending on the definition applied [10]. In older adults, myalgia or weakness may increase fall risk. One rationale for adding evolocumab is to allow statin dose reduction while maintaining LDL-C targets, potentially alleviating muscle symptoms.

In the GAUSS-3 trial, which enrolled statin-intolerant patients, evolocumab lowered LDL-C by 52.8% compared with 16.7% for ezetimibe, with muscle symptom rates comparable to ezetimibe and significantly lower than rechallenge with atorvastatin [11]. For geriatric patients who have discontinued statins due to myalgia, PCSK9 inhibitor monotherapy or combination with low-dose statin becomes a practical option.

No signal for increased fracture risk has appeared in evolocumab trials. A pooled analysis of over 6,000 patient-years of exposure found fracture rates of 1.7% in the evolocumab group versus 1.6% in the control group [8]. This is reassuring given earlier theoretical concerns that very low LDL-C might impair steroid hormone synthesis, which depends on cholesterol as a precursor. The data show no such effect.

Drug-Drug Interactions and Polypharmacy

The average adult over 65 takes five or more prescription medications [12]. Evolocumab has a favorable interaction profile because monoclonal antibodies are not metabolized by cytochrome P450 enzymes and do not inhibit or induce hepatic drug-metabolizing pathways [8].

There are no known clinically significant drug-drug interactions with evolocumab. It can be co-administered with statins, ezetimibe, anticoagulants, antihypertensives, and antidiabetic agents without dose modification. This is a meaningful advantage for geriatric prescribing, where each new agent must be evaluated against the existing medication list for interaction potential. Dr. Michael Shapiro, a preventive cardiologist at Wake Forest Baptist Health, has noted: "The clean drug interaction profile of PCSK9 inhibitors makes them particularly attractive in older patients who are already on complex regimens" [13].

The subcutaneous injection route also bypasses concerns about gastrointestinal absorption variability, which can be relevant in older patients with gastroparesis, altered gut motility, or enteral feeding.

Injection Site Reactions and Adherence

Injection site reactions (ISRs) occurred in 3.2% of evolocumab-treated patients versus 3.0% on placebo in FOURIER, a clinically negligible difference [1]. Reactions were predominantly mild (erythema, pruritus, bruising) and rarely led to discontinuation.

For geriatric patients, practical injection considerations matter as much as pharmacology. The SureClick autoinjector delivers the 140 mg dose in approximately 15 seconds and requires minimal hand strength. The Pushtronex system delivers the 420 mg monthly dose over about 5 minutes using an on-body infusor. A 2020 survey of patients aged 65 and older using the autoinjector reported 92% confidence in self-administration after a single training session [14].

Adherence data from the FOURIER-OLE extension showed that 73.5% of patients remained on therapy at 5 years, with rates not significantly different between those over and under 65 [4]. This compares favorably with real-world statin adherence, which drops below 50% at 1 year in many registries.

Deprescribing Considerations

Deprescribing, the systematic reduction of medications that may no longer provide net benefit, is a growing focus in geriatric medicine. For patients with limited life expectancy or significant frailty, the time-to-benefit of lipid-lowering therapy becomes a central question.

The FOURIER Kaplan-Meier curves showed separation for the key secondary endpoint (cardiovascular death, MI, or stroke) beginning at approximately 6 months [1]. This suggests that patients with a reasonable life expectancy of at least 1 to 2 years could derive meaningful benefit. The 2022 AHA scientific statement on lipid management in older adults recommends individualized decision-making, weighing ASCVD risk, functional status, patient preference, and life expectancy rather than applying rigid age cutoffs [15].

When deprescribing is appropriate, evolocumab can be stopped without rebound. LDL-C returns to pretreatment levels within 8 to 12 weeks after the last injection, and there is no withdrawal phenomenon or compensatory LDL-C overshoot [8]. This clean discontinuation pharmacology simplifies transitions in care.

Immunogenicity and Long-Term Antibody Exposure

Anti-drug antibodies (ADAs) are a theoretical concern with any biologic. In the pooled evolocumab safety database, binding antibodies were detected in 0.1% of patients, and no neutralizing antibodies were identified [8]. Among geriatric patients, who may have altered immune surveillance, the immunogenicity rate was not elevated compared with younger adults. Five-year data from FOURIER-OLE confirmed that ADA incidence remained below 0.3% with sustained dosing [4].

The half-life of evolocumab is approximately 11 to 17 days, and steady-state is achieved by the third dose regardless of the dosing interval chosen [8]. Age does not alter the pharmacokinetic profile based on population PK modeling that included patients up to 85 years old.

Practical Prescribing Summary for Patients Over 65

Start with a shared decision-making conversation that includes the patient's ASCVD history, current LDL-C on maximally tolerated therapy, life expectancy estimate, and preferences about injectable versus oral medication. If LDL-C remains ≥70 mg/dL (or ≥55 mg/dL per ESC targets) despite statin plus ezetimibe, evolocumab is a guideline-supported option without age-based restrictions.

Order a baseline lipid panel and check LDL-C 4 to 8 weeks after initiation. No renal or hepatic function monitoring is required specifically for evolocumab. Reassess at 3 to 6 months for efficacy, adherence, and injection technique, especially in patients with arthritis or visual impairment who may need caregiver assistance. If the patient's clinical trajectory shifts toward comfort-focused care, the drug can be discontinued without taper. Expect LDL-C to return to baseline within 12 weeks of the last dose [8].